Videos

Mechanical thrombectomy beats anticoagulation alone in STORM-PE
Highly anticipated trial data comparing mechanical thrombectomy to anticoagulation alone for intermediate- and high-risk pulmonary embolism showed that the more aggressive strategy improved outcomes.
ACC raises red flags over telehealth, payment reform and the cardiologist shortage
"We need telehealth the way we had it for COVID," Cathie Biga told Cardiovascular Business at TCT 2025. "We don't want to go back to having it so restricted."
Key takeaways for interventional cardiology from TCT 2025
B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more.
The push to get 3D echo into the congenital operating room
Nee Khoo, MBChB, director of the echocardiography lab at Canada's Stollery Children’s Hospital, explains the rapid adoption of pediatric 3D transesophageal echo.
Nuclear cardiology expands beyond perfusion imaging as it enters a new era
Beyond amyloidosis, nuclear cardiology is also increasingly used to image inflammation and infection in the myocardium, especially in diseases such as cardiac sarcoidosis and myocarditis.

Video Robert Lookstein on mechanical thrombectomy beating anticoagulation alone in pulmonary embolism in the late-breaking STORM-PE trial at TCT 2025.

Mechanical thrombectomy beats anticoagulation alone in STORM-PE

Highly anticipated trial data comparing mechanical thrombectomy to anticoagulation alone for intermediate- and high-risk pulmonary embolism showed that the more aggressive strategy improved outcomes.

At the recent American College of Cardiology (ACC) Legislative Committee meeting, leaders warned that ongoing federal policy uncertainty threatens patient access and the stability of cardiovascular care. Cathie Biga, MSM, immediate past president of the ACC, outlined growing concerns over telehealth, shrinking Medicare reimbursement, and mounting physician workforce shortages driven by visa restrictions.

ACC raises red flags over telehealth, payment reform and the cardiologist shortage

"We need telehealth the way we had it for COVID," Cathie Biga told Cardiovascular Business at TCT 2025. "We don't want to go back to having it so restricted."

Hadley Wilson, MD, MACC, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, and a clinical professor of medicine at Wake Forest University School of Medicine, shares what he felt were the most important clinical trials presented at the TCT 2025.

Key takeaways for interventional cardiology from TCT 2025

B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more.

Dr. Nee Khoo, director of the echocardiography lab, Stollery Children’s Hospital, Edmonton, Canada, explains the rapidly growing adoption of pediatric 3D transesophageal echo (TEE) to not only preplan, but also guide and assess the results of congenital heart surgeries.

The push to get 3D echo into the congenital operating room

Nee Khoo, MBChB, director of the echocardiography lab at Canada's Stollery Children’s Hospital, explains the rapid adoption of pediatric 3D transesophageal echo.

Nuclear cardiology is entering a new era—one that goes well beyond the traditional focus on myocardial perfusion imaging. According to Marcelo Di Carli, MD, editor-in-chief of the Journal of Nuclear Cardiology and chief of the Division of Nuclear Medicine at Brigham and Women’s Hospital, the field is rapidly expanding into diagnosing and monitoring complex cardiac diseases such as amyloidosis, sarcoidosis, myocarditis, and cardiac infections.

Nuclear cardiology expands beyond perfusion imaging as it enters a new era

Beyond amyloidosis, nuclear cardiology is also increasingly used to image inflammation and infection in the myocardium, especially in diseases such as cardiac sarcoidosis and myocarditis.

Daniel Addison, MD, Director of Translational Research in the Cardiology Division and Associate Director for Survivorship and Outcomes Research in the Harold C. Simmons Comprehensive Cancer Center. He also holds the Audre and Bernard Rapport Endowed Chair in Cardiovascular Research, UT Southwestern Medical Center. explains the health disparities and inequities involved in cardio-oncology.

How clinicians can combat health disparities in cardio-oncology

Researchers, for example, could improve disparities by performing their tests on more diverse groups of patients. Daniel Addison, MD, shared his perspective with Cardiovascular Business.

James Muller, MD, explains advances in vulnerable plaque imaging aim to predict and prevent heart attacks.

Advances in imaging could help predict, prevent heart attacks

Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away.

Marcelo Di Carli, MD, editor-in-Chief of the Journal of Nuclear Cardiology, chief, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, and executive director, Cardiovascular Imaging Program, at Brigham and Women's Hospital, explains why there is rapid growth of PET imaging because of the extra value it brings in detecting microvascular disease.

How PET is transforming cardiac nuclear imaging

"PET has changed the practice of nuclear medicine in general and I think it is going to revitalize the practice of cardiology," Marcelo Di Carli, MD, told Cardiovascular Business. He noted that more practices seem interested in implementing PET than ever before.